comparemela.com

Latest Breaking News On - Rebecca luse - Page 1 : comparemela.com

TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline

$158M Series B-2 Financing led by Deep Track Capital, with new participation from leading global biotechnology investors including RA Capital Management,.

Dave licataVince ruizRibociclib kisqaliMark allesPalbociclib ibranceDennis slamonPerceptive xontogeny venture fundSlamon research laboratoryBristol myers squibbDivision of hematology oncologyRoth zabelCrandon lawDavid geffen school of medicineDeep track capitalPerceptive advisorsAvidity partners

Mariana Oncology Raises $175M in Series B Funding

The firm will use the proceeds to develop radiopharmaceuticals, including its lead candidate poised to enter clinical trials next year in small cell lung cancer.

United statesGeert jan mulderEli lillyAtlas ventureMariana oncologyDeep track capitalAccess biotechnologyNextech investSurveyor capitalRebecca luse

Mariana Oncology Raises USD175M in Series B Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Geert jan mulderEli lillyAtlas ventureForbion ventures fundMariana oncologyDeep track capitalAccess biotechnologyNextech investSurveyor capitalForbion managing partner geert jan mulderRebecca luseSimon readChief executive officer

Apogee Therapeutics Launches with $169 Million to Develop Potentially Best-in-Class Therapies for Immunological and Inflammatory Disorders

Oversubscribed $149M Series B financing co-led by new investors Deep Track Capital and RTW Investments, LP adds to Series A investment from founding investors.

New zealand generalNew zealandSan franciscoUnited statesHussam shaheenMichael hendersonDunn crutcherPerceptive xontogeny ventures fundDrug administrationFidelity management research companyApogee therapeuticsDeep track capitalVenrock healthcare capital partnersParagon therapeuticsChief executive officerChief executive officer michael henderson

vimarsana © 2020. All Rights Reserved.